SCHEMBL6925099

SCHEMBL6925099

CC(C)(C)OC(=O)Cc1ccccc1O[C@H]1CCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.48
PRMT5 O14744 1/20 0.46
WDR77 Q9BQA1 1/20 0.46
KDM1A O60341 1/20 0.46
PDE4B Q07343 3/20 0.46
GPR119 Q8TDV5 4/20 0.46
PIK3CD O00329 4/20 0.45
PDE4A P27815 2/20 0.45
PDE4C Q08493 2/20 0.45
PDE4D Q08499 2/20 0.45
JAK2 O60674 1/20 0.44
JAK1 P23458 1/20 0.44
PIK3CA P42336 2/20 0.44
PIK3CB P42338 2/20 0.44
PIK3CG P48736 2/20 0.44
KDM4E B2RXH2 1/20 0.43
PKM P14618 1/20 0.43
CACNB4 O00305 1/20 0.43
CACNA1A O00555 1/20 0.43
CACNA1G O43497 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6926570 0.94 PDE4B (0.47) USP30PRMT5WDR77KDM1APDE4B
SCHEMBL6924027 0.92 L3MBTL1 (0.47) USP30PRMT5WDR77KDM1APDE4B
SCHEMBL6925955 0.91 GPR119 (0.48) USP30PRMT5WDR77KDM1APDE4B
SCHEMBL6929074 0.89 GPR119 (0.46) USP30PRMT5WDR77KDM1APDE4B
SCHEMBL18295360 0.88 GPR119 (0.50) USP30PRMT5WDR77KDM1APDE4B
SCHEMBL16814814 0.88 USP30 (0.49) USP30PRMT5WDR77KDM1APDE4B
SCHEMBL16792796 0.88 USP30 (0.49) USP30PRMT5WDR77KDM1APDE4B
SCHEMBL3111017 0.81 RBP4 (0.57) USP30PRMT5WDR77KDM1APDE4B
SCHEMBL3794778 0.81 KDM1A (0.54) USP30PRMT5WDR77KDM1APDE4B
SCHEMBL1927899 0.81 USP30 (0.52) USP30PRMT5WDR77KDM1APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515142-B2 Intermediates of aromatic amidine derivatives which have anticoagulation action DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-02-04 US disclosed
US-20020062033-A1 Process for preparing 2-phenyl-3-naphthylpropionic acid derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2002-05-23 US disclosed
US-6337405-B1 MULTISTAGE REACTION OF PYRROLE SUBSTITUTED WITH SULFONATE GROUPS AND HYDROXYPHENYLACETIC ACID DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2002-01-08 US disclosed
US-6252088-B1 COUPLING A NITRILE CONTAININ NAPHTHALENE COMPOUND WITH A COMPOUND CONTAINING PROPIONIC ACID GROUP DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-06-26 US disclosed
EP-0936215-A1 PROCESS FOR PREPARING 2-PHENYL-3-NAPHTHYLPROPIONIC ACID DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1999-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020062033-A1 Process for preparing 2-phenyl-3-naphthylpropionic acid derivatives PROC, F12, F2 USP30 3729/4885PRMT5 1292/4885WDR77 4474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.